Healthcare provider profile · identity verified

Michael John Sampognaro, M.D.

Internal Medicine · MONROE, LA · NPI 1194752865

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	424	97
Atorvastatin Calcium	Atorvastatin Calcium	379	110
Rosuvastatin Calcium	Rosuvastatin Calcium	326	89
Losartan Potassium	Losartan Potassium	305	75
Amlodipine Besylate	Amlodipine Besylate	303	76
Pantoprazole Sodium	Pantoprazole Sodium	253	61
Metoprolol Succinate	Metoprolol Succinate	251	70
Omeprazole	Omeprazole	236	62
Hydrochlorothiazide	Hydrochlorothiazide	227	57
Metformin Hcl	Metformin Hcl	219	58
Gabapentin	Gabapentin	216	53
Nifedipine Er	Nifedipine	208	45
Telmisartan	Telmisartan	200	53
Potassium Chloride	Potassium Chloride	153	39
Escitalopram Oxalate	Escitalopram Oxalate	145	36
Pravastatin Sodium	Pravastatin Sodium	139	37
Olmesartan Medoxomil	Olmesartan Medoxomil	131	31
Jardiance	Empagliflozin	126	20
Clopidogrel	Clopidogrel Bisulfate	119	32
Simvastatin	Simvastatin	116	29
Metoprolol Tartrate	Metoprolol Tartrate	110	31
Bumetanide	Bumetanide	109	34
Eliquis	Apixaban	106	18
Januvia	Sitagliptin Phosphate	103	14
Allopurinol	Allopurinol	100	27
Nebivolol Hcl	Nebivolol Hcl	98	20
Clonazepam	Clonazepam	93	12
Tamsulosin Hcl	Tamsulosin Hcl	83	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	81	24
Citalopram Hbr	Citalopram Hydrobromide	79	12
Ezetimibe	Ezetimibe	79	23
Doxazosin Mesylate	Doxazosin Mesylate	76	16
Doxepin Hcl	Doxepin Hcl	67	12
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	63	16
Furosemide	Furosemide	62	20
Meloxicam	Meloxicam	62	14
Warfarin Sodium	Warfarin Sodium	60	12
Fluoxetine Hcl	Fluoxetine Hcl	56	14
Metformin Hcl Er	Metformin Hcl	55	12
Carvedilol	Carvedilol	53	18
Lisinopril	Lisinopril	53	15
Donepezil Hcl	Donepezil Hcl	50	suppressed
Trazodone Hcl	Trazodone Hcl	49	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	47	13
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	47	suppressed
Atenolol	Atenolol	46	12
Esomeprazole Magnesium	Esomeprazole Magnesium	46	16
Montelukast Sodium	Montelukast Sodium	45	14
Levofloxacin	Levofloxacin	44	40
Sertraline Hcl	Sertraline Hcl	44	11
Finasteride	Finasteride	38	13
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	38	13
Amiodarone Hcl	Amiodarone Hcl	36	suppressed
Famotidine	Famotidine	36	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	28
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	33	21
Pioglitazone Hcl	Pioglitazone Hcl	33	suppressed
Spironolactone	Spironolactone	33	suppressed
Colchicine	Colchicine	32	suppressed
Glipizide	Glipizide	32	suppressed
Celecoxib	Celecoxib	31	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	28	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	27	25
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Amoxicillin	Amoxicillin	26	24
Mounjaro	Tirzepatide	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Chlorzoxazone	Chlorzoxazone	25	suppressed
Primidone	Primidone	25	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	23	20
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	12
Chlorthalidone	Chlorthalidone	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	17	suppressed
Ranolazine Er	Ranolazine	17	suppressed
Febuxostat	Febuxostat	16	suppressed
Ibandronate Sodium	Ibandronate Sodium	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Methimazole	Methimazole	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Pitavastatin Calcium	Pitavastatin Calcium	15	suppressed
Ramipril	Ramipril	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	14
Linzess	Linaclotide	14	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Edarbyclor	Azilsartan Med/Chlorthalidone	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Fenofibric Acid	Fenofibric Acid (Choline)	12	suppressed
Methylprednisolone	Methylprednisolone	12	11
Novolog Flexpen	Insulin Aspart	12	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	12	12
Ozempic	Semaglutide	12	suppressed
Perphenazine	Perphenazine	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Aspirin-Dipyridamole Er	Aspirin/Dipyridamole	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	11	suppressed
Novolog	Insulin Aspart	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error